Samsung Biologics Signs Multi-Product Development and Manufacturing Agreement with ImmuneOncia

 Samsung Biologics Signs Multi-Product Development and Manufacturing Agreement with ImmuneOncia

Samsung Biologics Signs Multi-Product Development and Manufacturing Agreement with ImmuneOncia

Shots:

  • The two companies expand their 2018 agreement to develop and manufacture five candidates from ImmuneOncia’s pipeline. The partners expand the collaboration to bring new treatments such as IMC-002 for cancer patients
  • Samsung Biologics to provide CDO services from cell line development, process development, non-clinical/clinical material manufacturing, to IND submission supporting the global clinical trials of five candidates
  • ImmuneOncia’s portfolio consists of immune checkpoint Abs including IMC-002, a CD47-targeting Ab, currently evaluating in global P-I study based on IND approval obtained through the development and manufacturing partnership with Samsung Biologics

Click here to read full press release/ article | Ref: PRNewswire | Image: LinkedIn

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post